A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • sponsor
    Incyte Corporation
Updated on 25 March 2021


A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma


The purpose of this study is to evaluate the safety/tolerability and efficacy of INCB039110 in combination with ibrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

For more information, please contact Incyte Corporation at 1.855.463.3463.

Condition Lymphoma, B-Cell
Clinical Study IdentifierTX147673
SponsorIncyte Corporation
Last Modified on25 March 2021


Yes No Not Sure

Inclusion Criteria

Histologically documented diagnosis of DLBCL. (Phase 1: any DLBCL subtype. Phase 2: activated B-cell or unclassifiable subtypes confirmed by immunohistochemistry using the Hans algorithm)
Relapsed or refractory DLBCL, defined as having received at least 1 but no more than 3 prior treatment regimens and ineligible for high-dose chemotherapy/autologous stem cell transplant
At least 1 measurable (= 2 cm in longest dimension) lesion on CT scan or magnetic resonance imaging (MRI)
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

Exclusion Criteria

Transformed DLBCL or DLBCL with coexistent histologies (eg, follicular or mucosa-associated lymphoid tissue lymphoma)
Primary mediastinal (thymic) large B-cell lymphoma
Known central nervous system lymphoma (either primary or metastatic)
Allogeneic stem cell transplant within the previous 6 months, or active graft versus host disease following allogeneic transplant
Use of immunosuppressive therapy within 28 days of starting study treatment. Immunosuppressive therapy includes but is not limited to cyclosporine A, tacrolimus, or high-dose corticosteroids. Subjects receiving corticosteroids must be at a dose level = 20 mg/day within 7 days of initiating study treatment
Prior or concurrent therapy with a Janus kinase inhibitor, Bruton's tyrosine kinase inhibitor, or lenalidomide (Phase 2 only)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note